Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis

Frontiers in Bioscience

Volumn 10, Issue SUPPL. 3, 2005, Pages 2932-2939

  Chen, Di ^a,b   Peng, Fangyu ^a,b   Cui, Qiuzhi Cindy ^a,b   Daniel, Kenyon G ^a,b   Orlu, Shirley ^a,b   Liu, Jiangguo ^b   Dou, Q Ping ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti copper drugs; Chelator; Copper; Drug discovery; PET; Proteasome inhibitors

Indexed keywords

COPPER COMPLEX; FLUORODEOXYGLUCOSE F 18; PROTEASOME; PYRROLIDINE DITHIOCARBAMATE; RADIOPHARMACEUTICAL AGENT; TETRATHIOMOLYBDIC ACID;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PROSTATE CANCER;

EID: 21344440550     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1749     Document Type: Article

References (52)

1. Labbe, S. and D.J. Thiele, Pipes and wiring: the regulation of copper uptake and distribution in yeast Trends Microbiol.12: 500-505 (1999)
2. Aggett, P.J. and S. Fairweather-Tait, Adaptation to high and low copper intakes: its relevance to estimated safe and adequate daily dietary intakes. Am J Clin Nutr.5 Suppl: 1061S-1063S (1998)
3. Habib, F.K., T.C. Dembinski, and S.R. Stitch, The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates. Clin Chim Acta.3: 329-335 (1980)
4. Nayak, S.B., V.R. Bhat, D. Upadhyay, and S.L. Udupa, Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian J Physiol Pharmacol.1: 108-110 (2003)
5. Margalioth, E.J., J.G. Schenker, and M. Chevion, Copper and zinc levels in normal and malignant tissues. Cancer.5: 868-872 (1983)
6. Kuo, H.W., S.F. Chen, C.C. Wu, D.R. Chen, and J.H. Lee, Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol Trace Elem Res.1: 1-11 (2002)
7. Sharma, K., D.K. Mittal, R.C. Kesarwani, V.P. Kamboj, and Chowdhery, Diagnostic and prognostic significance of serum and tissue trace elements in breast malignancy. Indian J Med Sci.10: 227-232 (1994)
8. Diez, M., M. Arroyo, F.J. Cerdan, M. Munoz, M.A. Martin, and J.L. Balibrea, Serum and tissue trace metal levels in lung cancer. Oncology.4: 230-234 (1989)
9. Scanni, A., L. Licciardello, M. Trovato, M. Tomirotti, and M. Biraghi, Serum copper and ceruloplasmin levels in patients with neoplasias localized in the stomach, large intestine or lung. Tumori.2: 175-180 (1977)
10. Turecky, L., P. Kalina, E. Uhlikova, S. Namerova, and J. Krizko, Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin Wochenschr.4: 187-189 (1984)
11. Chan, A., F. Wong, and M. Arumanayagam, Serum ultrafiltrable copper, total copper and caeruloplasmin concentrations in gynaecological carcinomas. Ann Clin Biochem: 545-549 (1993)
12. Eatock, M.M., A. Schatzlein, and S.B. Kaye, Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev.3: 191-204 (2000)
13. Dutcher, J.P., Angiogenesis and melanoma. Curr Oncol Rep.4: 353-358 (2001)
14. Fox, S.B., G. Gasparini, and A.L. Harris, Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol.5: 278-289 (2001)
15. Gourley, M. and J.S. Williamson, Angiogenesis: new targets for the development of anticancer chemotherapies. Curr Pharm Des.4: 417-439 (2000)
16. Ryan, C.J. and G. Wilding, Angiogenesis inhibitors. New agents in cancer therapy. Drugs Aging.4: 249-255 (2000)
17. Brewer, G.J., Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood)7: 665-673 (2001)
18. Brem, S., Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. Cancer Control.5: 436-458 (1999)
19. Theophanides, T. and J. Anastassopoulou, Copper and carcinogenesis. Crit Rev Oncol Hematol.1: 57-64 (2002)
20. Brewer, G.J., R.D. Dick, D.K. Grover, V. LeClaire, M. Tseng, M. Wicha, K. Pienta, B.G. Redman, T. Jahan, V.K. Sondak, M. Strawderman, G. LeCarpentier, and S.D. Merajver, Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res.1: 1-10 (2000)
21. Daniel, K.G., R.H. Harbach, W.C. Guida, and Q.P. Dou, Copper storage diseases: Menkes, Wilsons, and cancer. Front Biosci: 2652-2662 (2004)
22. Hochstrasser, M., Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol.2: 215-223 (1995)
23. Ciechanover, A., The ubiquitin-proteasome proteolytic pathway. Cell.1: 13-21 (1994)
24. Voges, D., P. Zwickl, and W. Baumeister, The 26S proteasome: a molecular machine designed for controlled proteolysis. Anna Rev Biochem: 1015-1068 (1999)
25. Seemuller, E., A. Lupas, D. Stock, J. Lowe, R. Huber, and W. Baumeister, Proteasome from Thermoplasma acidophilum: a threonine protease. Science.5210: 579-582 (1995)
26. An, B., R.H. Goldfarb, R. Siman, and Q.P. Dou, Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ.12: 1062-1075 (1998)
27. Adams, J., V.J. Palombella, E.A. Sausville, J. Johnson, A. Destree, D.D. Lazarus, J. Maas, C.S. Pien, S. Prakash, and P.J. Elliott, Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res.11: 2615-2622 (1999)
28. Imajoh-Ohmi, S., T. Kawaguchi, S. Sugiyama, K. Tanaka, S. Omura, and H. Kikuchi, Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun.3: 1070-1077 (1995)
29. Shinohara, K., M. Tomioka, H. Nakano, S. Tone, H. Ito, and S. Kawashima, Apoptosis induction resulting from proteasome inhibition Biochem J: 385-388 (1996)
30. Drexler, H.C., Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci U S A.3: 855-860 (1997)
31. Lopes, U.G., P. Erhardt, R. Yao, and G.M. Cooper, p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem.20: 12893-12896 (1997)
32. Malaguarnera, L., M.R. Pilastro, R. DiMarco, C. Scifo, M. Renis, M.C. Mazzarino, and A. Messina, Cell death in human acute myelogenous leukemic cells induced by pyrrolidinedithiocarbamate. Apoptosis.5: 539-545 (2003)
33. Schreck, R., B. Meier, D.N. Marmel, W. Droge, and P.A. Baeuerle, Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med.5: 1181-1194 (1992)
34. Orrenius, S., C.S. Nobel, D.J. van den Dobbelsteen, M.J. Burkitt, and A.F. Slater, Dithiocarbamates and the redox regulation of cell death. Biochem Soc Trans.4: 1032-1038 (1996)
35. Somers, P.K., R.M. Medford, and U. Saxena, Dithiocarbamates: effects on lipid hydroperoxides and vascular inflammatory gene expression. Free Radic Biol Med.10: 1532-1537 (2000)
36. Fernandez, P.C., J. Machado, Jr., V.T. Heussler, C. Botteron, G.H. Palmer, and D.A. Dobbelaere, The inhibition of NF-kappaB activation pathways and the induction of apoptosis by dithiocarbamates in T cells are blocked by the glutathione precursor N-acetyl-L-cysteine. Biol Chem.12: 1383-1394 (1999)
37. Furuta, S., F. Ortiz, X. Zhu Sun, H.H. Wu, A. Mason, and J. Momand, Copper uptake is required for pyrrolidine dithiocarbamate-mediated oxidation and protein level increase of p53 in cells. Biochem J.Pt 3: 639-648 (2002)
38. Doytcheva, M.A. and B.G. Jeliazkova, Structure of copper(II) dithiocarbamate mixed-ligand complexes and their photoreactivities in alcohols. Spectrochim Acta A Mol Biomol Spectrosc.6: 1299-1305 (2004)
39. Cen, D., D. Brayton, B. Shahandeh, F.L. Meyskens, Jr., and P.J. Farmer, Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem.21: 6914-6920 (2004)
40. Pan, Q., C.G. Kleer, K.L. van Golen, J. Irani, K.M. Bottema, C. Bias, M. De Carvalho, E.A. Mesri, D.M. Robins, R.D. Dick, G.J. Brewer, and S.D. Merajver, Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res.17: 4854-4859 (2002)
41. Khan, M.K., M.W. Miller, J. Taylor, N.K. Gill, R.D. Dick, K. Van Golen, G.J. Brewer, and S.D. Merajver, Radiotherapy and antiangiogenic TM in lung cancer. Neoplasia.2: 164-170 (2002)
42. Daniel, K.G., P. Gupta, R.H. Harbach, W.C. Guida, and Q.P. Dou, Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol.6: 1139-1151 (2004)
43. 18F]fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 27:235-238, (1986)
44. An, B. and Q.P. Dou, Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate. Cancer Res.3: 438-442 (1996)
45. Chen, M.S., D. Chen, and Q.P. Dou, Inhibition of proteasome activity by various fruits and vegetables is associated with cancer cell death. In Vivo.1: 73-80 (2004)
46. Spataro, V., C. Norbury, and A.L. Harris, The ubiquitin-proteasome pathway in cancer. Br J Cancer.3: 448-455 (1998)
47. Dou, Q.P. and B. Li, Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat.4: 215-223 (1999)
48. Dou, Q.P. and R.H. Goldfarb, Bortezomib (millennium pharmaceuticals) IDrugs.8: 828-834 (2002)
49. Markovic, S.N., S.M. Geyer, F. Dawkins, W. Sharfman, M. Albertini, W. Maples, P.M. Fracasso, T. Fitch, P. Lorusso, A.A. Adjei, and C. Erlichman, A phase II study of bortezomib in the treatment of metastatic malignant melanoma Cancer (2005)
50. Adams, J., Development of the proteasome inhibitor PS-341. Oncologist.1: 9-16 (2002)
51. Almond, J.B. and G.M. Cohen, The proteasome: a novel target for cancer chemotherapy. Leukemia.4: 433-443 (2002)
52. Dou, Q.P. and S. Nam, Pharmacological proteasome inhibitors and their therapeutic potential. Exp. Opin. Ther. Patents.10: 1263-1272 (2000)